info:eu-repo/semantics/article
The Trypanosoma cruzi TcTASV-C protein subfamily administrated with U-Omp19 promotes a protective response against a lethal challenge in mice
Fecha
2020-11Registro en:
Caeiro, Lucas Daniel; Masip, Yamil Ezequiel; Rizzi, Mariana; Rodriguez, Matias Exequiel; Pueblas Castro, Celeste Victoria; et al.; The Trypanosoma cruzi TcTASV-C protein subfamily administrated with U-Omp19 promotes a protective response against a lethal challenge in mice; Elsevier; Vaccine; 38; 48; 11-2020; 7645-7653
0264-410X
CONICET Digital
CONICET
Autor
Caeiro, Lucas Daniel
Masip, Yamil Ezequiel
Rizzi, Mariana
Rodriguez, Matias Exequiel
Pueblas Castro, Celeste Victoria
Sanchez, Daniel Oscar
Coria, Mirta Lorena
Cassataro, Juliana
Tekiel, Valeria Sonia
Resumen
The development of a Chagaś disease vaccine has yet the need for the identification of novel combinations of antigens and adjuvants. Here, the performance of TcTASV-C proteins that are virulence factors of trypomastigotes and belong to a novel surface protein family specific for T. cruzi, have been evaluated as antigens for a prophylactic vaccine. Several immunization schemes in which TcTASV-C was combined with aluminum hydroxide, saponin and/or U-Omp19 were assayed. Aluminum hydroxide and saponin were assayed together to trigger different pathways of the immune response simultaneously. U-Omp19 is a promising novel adjuvant able to promote a Th1 immune response with IFNg production, thus an interesting molecule to be tested as adjuvant for the control of T. cruzi infection. Therefore, U-Omp19 was added to the aluminum hydroxide-saponin formulation as well as assayed individually with TcTASV-C. The immunization with TcTASV-C and U-Omp19 had the best performance as a prophylactic vaccine. Mice presented the lowest parasitemias and improved survival by 40% after being challenged with a highly virulent T. cruzi strain, which promoted 100% mortality in all other immunized groups. Immunization with TcTASV-C and U-Omp19 triggered cellular responses with IFN-γ and IL-17 production and with lytic antibodies that could explain the protection achieved by this vaccination scheme. To our knowledge, this is the first time that U-Omp19 is tested with a defined T. cruzi antigen in a vaccine formulation.